VEGF (Vascular endothelial growth factor) and fibrotic lung disease

International Journal of Molecular Sciences

Volumn 19, Issue 5, 2018, Pages

  Barratt, Shaney L ^a   Flower, Victoria A ^b   Pauling, John D ^b   Millar, Ann B ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b University of Bath   (United Kingdom)

Author keywords

Fibrosis; Interstitial lung disease; Vascular endothelial growth factor; VEGF

Indexed keywords

NEUROPILIN 1; NEUROPILIN 2; NINTEDANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR;

ALLERGIC PNEUMONITIS; BIOAVAILABILITY; CELL MIGRATION; CELL SURVIVAL; FIBROSING ALVEOLITIS; HOMEOSTASIS; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG FIBROSIS; LUNG PARENCHYMA; NONHUMAN; ORGANOGENESIS; PATHOGENESIS; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SYSTEMIC SCLEROSIS; ANIMAL; CHEMISTRY; DISEASE PREDISPOSITION; GENETICS; METABOLISM; PATHOLOGY;

ANIMALS; DISEASE SUSCEPTIBILITY; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG DISEASES, INTERSTITIAL; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 85046080862     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms19051269     Document Type: Review

References (146)

1. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am. J. Respir. Crit. Care Med. 2001, 165, 277–304.
2. Richeldi, L.; du Bois, R.M.; Raghu, G.; Azuma, A.; Brown, K.; Costabel, U.; Cottin, V.; Flaherty, K.R.; Hansell, D.M.; Yoshikazu, I. et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014, 370, 2071–2082 [CrossRef] [PubMed]
3. Ferrara, N.; Gerger, H.P.; Lecouter, J. The biology of VEGF and its receptors. Nat. Med. 2003, 9, 669–676 [CrossRef] [PubMed]
4. Leung, D.W.; Cachianes, G.; Kuang, W.J.; Goeddel, D.V.; Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246, 1306–1309 [CrossRef] [PubMed]
5. Zacchigna, S.; Lambrechts, D.; Carmeliet, P. Neurovascular signaling defects in neurodegeneration. Nat. Rev. Neurosci. 2008, 9, 169–181 [CrossRef] [PubMed]
6. Harper, S.J.; Bates, D.O. VEGF-A splicing: The key to anti-angiogenic therapeutics? Nat. Rev. Cancer 2008, 8, 880–887 [CrossRef] [PubMed]
7. Bates, D.O. Vascular endothelial growth factors and vascular permeability. Cardiovasc. Res. 2010, 87, 262–271 [CrossRef] [PubMed]
8. Bates, D.O.; Cui, T.G.; Doughty, J.M.; Winkler, M.; Sugiono, M.; Shields, J.D.; Peat, D.; Gillatt, D.; Harper, S.J. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res. 2002, 62, 4123–4131 [PubMed]
9. Woolard, J.; Wang, W.Y.; Bevan, H.S.; Qiu, Y.; Morbidelli, L.; Pritchard-Jones, R.O.; Cui, T.G.; Sugiono, M.; Waine, E.; Perrin, R. et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: Mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 2004, 64, 7822–7835 [CrossRef] [PubMed]
10. Cebe Suarez, S.; Pieren, M.; Cariolato, L.; Arn, S.; Hoffmann, U.; Bogucki, A.; Manlius, C.; Wood, J.; Ballmer-Hofer, K. A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2. Cell. Mol. Life Sci. 2006, 63, 2067–2077 [CrossRef] [PubMed]
11. Bates, D.O.; Qiu, Y.; Cater, J.G.; Hamdollah-Zadeh, M.; Barratt, S.; Gammons, M.V.; Millar, A.B.; Salmon, A.H.J.; Oltean, S.; Haeper, S.J. Detection of VEGF-A(xxx)b isoforms in human tissues. PLoS ONE 2013, 8, e68399 [CrossRef] [PubMed]
12. Olofsson, B.; Korpelainen, E.; Pepper, M.S.; Mandriota, S.J.; Aase, K.; Kumar, V.; Gunji, Y.; Jeltsch, M.M.; Shibuya, M.; Alitalo, K. et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc. Natl. Acad. Sci. USA 1998, 95, 11709–11714 [CrossRef] [PubMed]
13. Joukov, V.; Pajusola, K.; Kaipainen, A.; Chilov, D.; Lahtinen, I.; Kukk, E.; Saksela, O.; Kalkkinen, N.; Alitalo, K. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996, 15, 290–298 [PubMed]
14. Olofsson, B.; Pajusola, K.; Kaipainen, A.; Von Eular, G.; Joukov, V.; Saksela, O.; Orpana, A.; Pettersson, R.F.; Alitalo, K.; Eriksson, U. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc. Natl. Acad. Sci. USA 1996, 93, 2576–2581 [CrossRef] [PubMed]
15. Wanstall, J.C.; Gambino, A.; Jeffrey, T.K.; Cahill, M.M.; Bellomo, D.; Hayward, N.K.; Kay, G.F. Vascular endothelial growth factor-B-deficient mice show impaired development of hypoxic pulmonary hypertension. Cardiovasc. Res. 2002, 55, 361–368 [CrossRef]
16. Wirzenius, M.; Tammela, T.; Uutela, M.; He, Y.; Odorisio, T.; Zambruno, G.; Nagy, J.A.; Dvorak, H.F.; Yla-Herttuala, S.; Shibuya, M. et al. Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting. J. Exp. Med. 2007, 204, 1431–1440 [CrossRef] [PubMed]
17. Saaristo, A.; Veikkola, T.; Enholm, B.; Hytonen, M.; Arola, J.; Pajusola, K.; Turunen, P.; Jeltsch, M.; Karkkainen, M.J.; Kerjaschki, D. et al. Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes. FASEB J. 2002, 16, 1041–1049 [CrossRef] [PubMed]
18. Ogawa, S.; Oku, A.; Sawano, A.; Yamaguchi, S.; Yazaki, Y.; Shibuya, M. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J. Biol. Chem. 1998, 273, 31273–31282 [CrossRef] [PubMed]
19. DiPalma, T.; Tucci, M.; Russo, G.; Maglione, D.; Lago, C.T.; Romano, A.; Saccone, S.; Della Valle, G.; De Gregorio, L.; Dragani, T.A. et al. The placenta growth factor gene of the mouse. Mamm. Genome 1996, 7, 6–12 [CrossRef] [PubMed]
20. Cao, Y. Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci. Signal. 2009, 2 [CrossRef] [PubMed]
21. Eriksson, A.; Cao, R.; Pawliuk, R.; Berg, S.M.; Tsang, M.; Zhou, D.; Fleet, C.; Tritsaris, K.; Dissing, S.; Leboulch, P. et al. Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. Cancer Cell 2002, 1, 99–108 [CrossRef]
22. Carmeliet, P.; Moons, L.; Luttun, A.; Vincenti, V.; Compernolle, V.; De Mol, M.; Wu, Y.; Bono, F.; Devy, L.; Beck, H. et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 2001, 7, 575–583 [CrossRef] [PubMed]
23. Matsumoto, T.; Claesson-Welsh, L. VEGF receptor signal transduction. Sci. STKE 2001, 2001 [CrossRef] [PubMed]
24. Shalaby, F.; Rossant, J.; Yamaguchi, T.P.; Gertsenstein, M.; Wu, X.F.; Breitman, M.L.; Schuh, A.C. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995, 376, 62–66 [CrossRef] [PubMed]
25. Fehrenbach, H.; Kasper, M.; Haase, M.; Schuh, D.; Muller, M. Differential immunolocalization of VEGF in rat and human adult lung, and in experimental rat lung fibrosis: Light, fluorescence, and electron microscopy. Anat. Rec. 1999, 254, 61–73 [CrossRef]
26. De Vries, C.; Escobedo, J.A.; Ueno, H.; Houck, K.; Ferrara, N.; Williams, L.T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992, 255, 989–991 [CrossRef] [PubMed]
27. Sawano, A.; Iwai, S.; Sakurai, Y.; Ito, M.; Shitara, K.; Nakahata, T.; Shibuya, M. Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood 2001, 97, 785–791 [CrossRef] [PubMed]
28. Maniscalco, W.M.; Watkins, R.H.; D’Angio, C.T.; Ryan, R.M. Hyperoxic injury decreases alveolar epithelial cell expression of vascular endothelial growth factor (VEGF) in neonatal rabbit lung. Am. J. Respir. Cell Mol. Biol. 1997, 16, 557–567 [CrossRef] [PubMed]
29. Medford, A.R.; Douglas, S.K.; Godinho, S.I.; Uppington, K.M.; Armstrong, L.; Gillespie, K.M.; Van Zyl, B.; Tetley, T.D.; Ibrahim, N.B.; Millar, A.B. Vascular Endothelial Growth Factor (VEGF) isoform expression and activity in human and murine lung injury. Respir. Res. 2009, 10, 27 [CrossRef] [PubMed]
30. Waltenberger, J.; Claesson-Welsh, L.; Siegbahn, A.; Shibuya, M.; Heldin, C.H. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J. Biol. Chem. 1994, 269, 26988–26995 [PubMed]
31. Kendall, R.L.; Thomas, K.A. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. USA 1993, 90, 10705–10709 [CrossRef] [PubMed]
32. Kanno, S.; Oda, N.; Abe, M.; Terai, Y.; Ito, M.; Shitara, K.; Tabayashi, K.; Shibuya, M.; Sato, Y. Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. Oncogene 2000, 19, 2138–2146 [CrossRef] [PubMed]
33. Zhang, F.; Tang, Z.; Hou, X.; Lennartsson, J.; Li, Y.; Koch, A.W.; Scotney, P.; Lee, C.; Arjunan, P.; Dong, L. et al. VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc. Natl. Acad. Sci. USA 2009, 106, 6152–6157 [CrossRef] [PubMed]
34. Neufeld, G.; Cohen, T.; Gengrinovitch, S.; Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999, 13, 9–22 [CrossRef] [PubMed]
35. Grunewald, F.S.; Prota, A.E.; Giese, A.; Ballmer-Hofer, K. Structure-function analysis of VEGF receptor activation and the role of coreceptors in angiogenic signaling. Biochim. Biophys. Acta 2010, 1804, 567–580 [CrossRef] [PubMed]
36. Ishida, A.; Murray, J.; Saito, Y.; Kanthou, C.; Benzakour, O.; Shibuya, M.; Wijelath, E.S. Expression of vascular endothelial growth factor receptors in smooth muscle cells. J. Cell. Physiol. 2001, 188, 359–368 [CrossRef] [PubMed]
37. Le, A.; Zielinski, R.; He, C.; Crow, M.T.; Biswal, S.; Tuder, R.M.; Becker, P.M. Pulmonary epithelial neuropilin-1 deletion enhances development of cigarette smoke-induced emphysema. Am. J. Respir. Crit. Care Med. 2009, 180, 396–406 [CrossRef] [PubMed]
38. Farkas, L.; Gauldie, J.; Voelkel, N.F.; Kolb, M. Pulmonary hypertension and idiopathic pulmonary fibrosis: A tale of angiogenesis, apoptosis, and growth factors. Am. J. Respir. Cell Mol. Biol. 2011, 45, 1–15 [CrossRef] [PubMed]
39. Accrregui, M.J.; Penisten, S.T.; Goss, K.L.; Ramirez, K.; Snyder, J.M. Vascular endothelial growth factor gene expression in human fetal lung in vitro. Am. J. Respir. Cell Mol. Biol. 1999, 20, 14–23 [CrossRef] [PubMed]
40. Ng, Y.S.; Rohan, R.; Sunday, M.E.; Demello, N.G.; D’Amore, P.A. Differential expression of VEGF isoforms in mouse during development and in the adult. Dev. Dyn. 2001, 220, 112–121 [CrossRef]
41. Galambos, C.; Ng, Y.S.; Ali, A.; Noguchi, A.; Lovejoy, S.; D’Amore, P.A.; Demello, D.E. Defective pulmonary development in the absence of heparin-binding vascular endothelial growth factor isoforms. Am. J. Respir. Cell Mol. Biol. 2002, 27, 194–203 [CrossRef] [PubMed]
42. Mura, M.; Binnie, M.; Han, B.; Li, C.; Andrade, C.F.; Shiozaki, A.; Zhang, Y.; Ferrara, N.; Hwang, D.; Waddell, T.K. et al. Functions of type II pneumocyte-derived vascular endothelial growth factor in alveolar structure, acute inflammation, and vascular permeability. Am. J. Pathol. 2010, 176, 1725–1734 [CrossRef] [PubMed]
43. Janer, J.; Lassus, P.; Haglund, C.; Paavonen, K.; Alitalo, K.; Andersson, S. Pulmonary vascular endothelial growth factor-C in development and lung injury in preterm infants. Am. J. Respir. Crit. Care Med. 2006, 174, 326–330 [CrossRef] [PubMed]
44. De Paepe, M.E.; Greco, D.; Mao, Q. Angiogenesis-related gene expression profiling in ventilated preterm human lungs. Exp. Lung Res. 2010, 36, 399–410 [CrossRef] [PubMed]
45. Greenberg, J.M.; Thompson, F.Y.; Brooks, S.K.; Shannon, J.M.; McCormick-Shannon, K.; Cameron, J.E.; Mallory, B.P.; Akeson, A.L. Mesenchymal expression of vascular endothelial growth factors D and A defines vascular patterning in developing lung. Dev. Dyn. 2002, 224, 144–153 [CrossRef] [PubMed]
46. Janer, J.; Andersson, S.; Haglund, C.; Karikoski, R.; Lassus, P. Placental growth factor and vascular endothelial growth factor receptor-2 in human lung development. Pediatrics 2008, 122, 340–346 [CrossRef] [PubMed]
47. Thurlbeck, W.M. Postnatal human lung growth. Thorax 1982, 37, 564–571 [CrossRef] [PubMed]
48. Jakkula, M.; Le Cras, T.D.; Gebb, S.; Hirth, K.P.; Tuder, R.M.; Voelkel, N.F.; Abman, S.H. Inhibition of angiogenesis decreases alveolarization in the developing rat lung. Am. J. Physiol. Lung Cell. Mol. Physiol. 2000, 279, L600–L607 [CrossRef] [PubMed]
49. McGrath-Morrow, S.A.; Cho, C.; Zhen, L.; Hicklin, D.J.; Tuder, R.M. Vascular endothelial growth factor receptor 2 blockade disrupts postnatal lung development. Am. J. Respir. Cell Mol. Biol. 2005, 32, 420–427 [CrossRef] [PubMed]
50. Berse, B.; Brown, L.F.; Van deWater, L.; Dvorak, H.F.; Senger, D.R. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol. Biol. Cell 1992, 3, 211–220 [CrossRef] [PubMed]
51. Kaner, R.J.; Crystal, R.G. Compartmentalization of vascular endothelial growth factor to the epithelial surface of the human lung. Mol. Med. 2001, 7, 240–246 [PubMed]
52. Barratt, S.L.; Blythe, T.; Jarrett, C.; Ourradi, K.; Shelley-Fraser, G.; Day, M.J.; Qiu, Y.; Harper, S.; Maher, T.M.; Oltean, S. et al. Differential Expression of VEGF-Axxx Isoforms Is Critical for Development of Pulmonary Fibrosis. Am. J. Respir. Crit. Care Med. 2017, 196, 479–493 [CrossRef] [PubMed]
53. Yao, J.S.; Shen, F.; Young, W.L.; Yang, G.Y. Comparison of doxycycline and minocycline in the inhibition of VEGF-induced smooth muscle cell migration. Neurochem. Int. 2007, 50, 524–530 [CrossRef] [PubMed]
54. Wu, W.K.; Llewellyn, O.P.; Bates, D.O.; Nicholson, L.B.; Dick, A.D. IL-10 regulation of macrophage VEGF production is dependent on macrophage polarisation and hypoxia. Immunobiology 2010, 215, 796–803 [CrossRef] [PubMed]
55. Medford, A.R.; Ibrahim, N.B.; Millar, A.B. Vascular endothelial growth factor receptor and coreceptor expression in human acute respiratory distress syndrome. J. Crit. Care 2009, 24, 236–242 [CrossRef] [PubMed]
56. Fujio, Y.; Walsh, K. Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J. Biol. Chem. 1999, 274, 16349–16354 [CrossRef] [PubMed]
57. Soker, S.; Fidder, H.; Neufeld, G.; Klagbrun, M. Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain. J. Biol. Chem. 1996, 271, 5761–5767 [CrossRef] [PubMed]
58. Medford, A.R.; Millar, A.B. Vascular endothelial growth factor (VEGF) in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): Paradox or paradigm? Thorax 2006, 61, 621–626 [CrossRef] [PubMed]
59. Brown, K.R.; England, K.M.; Goss, K.L.; Snyder, J.M.; Acarregui, M.J. VEGF induces airway epithelial cell proliferation in human fetal lung in vitro. Am. J. Physiol. Lung Cell. Mol. Physiol. 2001, 281, L1001–L1010 [CrossRef] [PubMed]
60. Varet, J.; Douglas, S.K.; Gilmartin, L.; Medford, A.R.; Bates, D.O.; Harper, S.J.; Millar, A.B. VEGF in the lung: A role for novel isoforms. Am. J. Physiol. Lung Cell. Mol. Physiol. 2016, 298, L768–L774 [CrossRef] [PubMed]
61. Compernolle, V.; Brusselmans, K.; Acker, T.; Hoet, P.; Tjwa, M.; Beck, H.; PLaisance, S.; Dor, Y.; Keshet, E.; Lupu, F. et al. Loss of HIF-2α and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat. Med. 2002, 8, 702–710 [CrossRef] [PubMed]
62. Mura, M.; Han, B.; Andrade, C.F.; Seth, R.; Hwang, D.; Waddell, T.K.; Keshavjee, S.; Liu, M. The early responses of VEGF and its receptors during acute lung injury: Implication of VEGF in alveolar epithelial cell survival. Crit. Care 2006, 10, R130 [CrossRef] [PubMed]
63. Roberts, J.R.; Perkins, G.D.; Fujisawa, T.; Pettigrew, K.A.; Gao, F.; Ahmed, A.; Thickett, D.R. Vascular endothelial growth factor promotes physical wound repair and is anti-apoptotic in primary distal lung epithelial and A549 cells. Crit. Care Med. 2007, 35, 2164–2170 [CrossRef] [PubMed]
64. Kuhn, H.; Kruger, S.; Hammerschmidt, S.; Wirtz, H. High concentrations of vascular endothelial growth factor reduce stretch-induced apoptosis of alveolar type II cells. Respirology 2010, 15, 343–348 [CrossRef] [PubMed]
65. Gerber, H.P.; Dixit, V.; Ferrara, N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J. Biol. Chem. 1998, 273, 13313–13316 [CrossRef] [PubMed]
66. Gerber, H.P.; McMurtrey, A.; Kowalski, J.; Yan, M.; Keyt, B.A.; Dixit, V.; Ferrara, N. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 30-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem. 1998, 273, 30336–30343 [CrossRef] [PubMed]
67. Alavi, A.; Hood, J.D.; Frausto, R.; Stupack, D.G.; Cheresh, D.A. Role of Raf in vascular protection from distinct apoptotic stimuli. Science 2003, 301, 94–96 [CrossRef] [PubMed]
68. Kasahara, Y.; Tuder, R.M.; Taraseviciene-Stewart, L.; Le Cras, T.D.; Abman, S.; Hirth, P.K.; Waltenberger, J.; Voelkel, N.F. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J. Clin. Investig. 2000, 106, 1311–1319 [CrossRef] [PubMed]
69. Tang, K.; Rossiter, H.B.; Wagner, P.D.; Breen, E.C. Lung-targeted VEGF inactivation leads to an emphysema phenotype in mice. J. Appl. Physiol. 2004, 97, 1559–1566 [CrossRef] [PubMed]
70. Tuder, R.M.; Kasahara, Y.; Voelkel, N.F. Inhibition of vascular endothelial growth factor receptors causes emphysema in rats. Chest 2000, 117, 281S [CrossRef]
71. Le Cras, T.D.; Spitzmiller, R.E.; Albertine, K.H.; Greenberg, J.M.; Whitsett, J.A.; Akeson, A.L. VEGF causes pulmonary hemorrhage, hemosiderosis, and air space enlargement in neonatal mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 2004, 287, L134–L142 [CrossRef] [PubMed]
72. Bhandari, V.; Chho-Wing, R.; Chapoval, S.P.; Lee, C.G.; Tang, C.; Kim, Y.K.; Ma, B.; Baluk, P.; Lin, M.I.; McDonald, D.M. et al. Essential role of nitric oxide in VEGF-induced, asthma-like angiogenic, inflammatory, mucus, and physiologic responses in the lung. Proc. Natl. Acad. Sci. USA 2006, 103, 11021–11026 [CrossRef] [PubMed]
73. Tsao, P.N.; Su, Y.N.; Li, H.; Huang, P.H.; Chien, C.T.; Lai, Y.L.; Lee, C.N.; Chen, C.A.; Cheng, W.F.; Wei, S.C. et al. Overexpression of placenta growth factor contributes to the pathogenesis of pulmonary emphysema. Am. J. Respir. Crit. Care Med. 2004, 169, 505–511 [CrossRef] [PubMed]
74. Ranieri, V.M.; Rubenfeld, G.D.; Thompson, B.T.; Ferguson, N.D.; Caldwell, E.; Fan, E.; Camporota, L.; Slutsky, A.S. Acute respiratory distress syndrome: The Berlin Definition. ARDS Definition Task Force. JAMA 2012, 307, 2526–2533 [PubMed]
75. Ware, L.B.; Matthay, M.A. The acute respiratory distress syndrome. N. Engl. J. Med. 2000, 342, 1334–1349 [CrossRef] [PubMed]
76. Barratt, S.; Medford, A.R.; Millar, A.B. Vascular endothelial growth factor in acute lung injury and acute respiratory distress syndrome. Respiration 2014, 87, 329–342 [CrossRef] [PubMed]
77. Medford, A.R.; Godinho, S.I.; Keen, L.J.; Bidwell, J.L.; Millar, A.B. Relationship between vascular endothelial growth factor + 936 genotype and plasma/epithelial lining fluid vascular endothelial growth factor protein levels in patients with and at risk for ARDS. Chest 2009, 136, 457–464 [CrossRef] [PubMed]
78. Medford, A.R.; Keen, L.J.; Bidwell, J.L.; Millar, A.B. Vascular endothelial growth factor gene polymorphism and acute respiratory distress syndrome. Thorax 2005, 60, 244–248 [CrossRef] [PubMed]
79. Yang, S.; Cao, S.; Li, J.; Chang, J. Association between vascular endothelial growth factor + 936 genotype and acute respiratory distress syndrome in a Chinese population. Genet. Test. Mol. Biomark. 2011, 15, 737–740 [CrossRef] [PubMed]
80. Song, J.; Lu, H.; Zheng, X.; Huang, X. Effects of vascular endothelial growth factor in recovery phase of acute lung injury in mice. Lung 2015, 193, 1029–1036 [CrossRef] [PubMed]
81. Thickett, D.R.; Armstrong, L.; Millar, A.B. A role for vascular endothelial growth factor in acute and resolving lung injury. Am. J. Respir. Crit. Care Med. 2002, 166, 1332–1337 [CrossRef] [PubMed]
82. Maitre, B.; Boussat, S.; Jean, D.; Gouge, M.; Brochard, L.; Housset, B.; Adnot, S.; Delclaux, C. Vascular endothelial growth factor synthesis in the acute phase of experimental and clinical lung injury. Eur. Respir. J. 2001, 18, 100–106 [CrossRef] [PubMed]
83. Azamfirei, L.; Gurzu, S.; Solomon, R.; Copotoiu, R.; Copotoiu, S.; Jung, I.; Tilinca, M.; Branzaniuc, K.; Corneci, D.; Szederjesi, J. et al. Vascular endothelial growth factor: A possible mediator of endothelial activation in acute respiratory distress syndrome. Minerva Anestesiol. 2010, 76, 609–616 [PubMed]
84. Maniscalco, W.M.; Watkins, R.H.; Finkelstein, J.N.; Campbell, M.H. Vascular endothelial growth factor mRNA increases in alveolar epithelial cells during recovery from oxygen injury. Am. J. Respir. Cell Mol. Biol. 1995, 13, 377–386 [CrossRef] [PubMed]
85. He, C.H.; Waxman, A.B.; Lee, C.G.; Link, H.; Ra-bach, M.E.; Ma, B.; Chen, Q.; Zhu, Z.; Zhong, M.; Nakayama, K. et al. Bcl-2-related protein A1 is an endogenous and cytokine-stimulated mediator of cytoprotection in hyperoxic acute lung injury. J. Clin. Investig. 2005, 115, 1039–1048 [CrossRef] [PubMed]
86. Kaner, R.J.; Ladetto, J.V.; Singh, R.; Fukuda, N.; Matthay, M.A.; Crystal, R.G. Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema. Am. J. Respir. Cell Mol. Biol. 2000, 22, 657–664 [CrossRef] [PubMed]
87. Watanabe, M.; Boyer, J.L.; Crystal, R.G. Genetic delivery of bevacizumab to suppress vascular endothelial growth factor-induced high-permeability pulmonary oedema. Hum. Gene Ther. 2009, 20, 598–610 [CrossRef] [PubMed]
88. Olson, A.L.; Swigris, J.J.; Lezotte, D.C.; Norris, J.M.; Wilson, C.G.; Brown, K.K. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am. J. Respir. Crit. Care Med. 2007, 176, 277–284 [CrossRef] [PubMed]
89. Navaratnam, V.; Fleming, K.M.; West, J.; Smith, C.J.; Jenkins, R.G.; Fogarty, A.; Hubbard, R.B. The rising incidence of idiopathic pulmonary fibrosis in the U.K. Thorax 2011, 66, 462–467 [CrossRef] [PubMed]
90. Collard, H.R.; King, T.E., Jr.; Bartelson, B.B.; Vourlekis, J.S.; Schwarz, M.I.; Brown, K.K. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2003, 168, 538–542 [CrossRef] [PubMed]
91. Raghu, G.; Weycker, D.; Edelsberg, J.; Bradford, W.Z.; Oster, G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2006, 174, 810–816 [CrossRef] [PubMed]
92. Noble, P.W.; Albera, C.; Bradford, W.Z.; Costabel, U.; Glassberg, M.K.; Kardatzke, D.; King, T.K., Jr.; Lancaster, L.; Sahn, S.A.; Szwarcberg, J. et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials. Lancet 2016, 377, 1760–1769 [CrossRef]
93. Katzenstein, A.L.; Mukhopadhyay, S.; Myers, J.L. Diagnosis of usual interstitial pneumonia and distinction from other fibrosing interstitial lung diseases. Hum. Pathol. 2008, 39, 1275–1294 [CrossRef] [PubMed]
94. Cosgrove, G.P.; Brown, K.K.; Schiemann, W.P.; Serls, A.E.; Parr, J.E.; Geraci, M.W.; Schwarz, M.I.; Cool, C.D.; Worten, G.S. Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: A role in aberrant angiogenesis. Am. J. Respir. Crit. Care Med. 2004, 170, 242–251 [CrossRef] [PubMed]
95. Ebina, M.; Shimizukawa, M.; Shibata, N.; Kimura, Y.; Suzuki, T.; Endo, M.; Sasano, H.; Kondo, T.; Nukiwa, T. Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2004, 169, 1203–1208 [CrossRef] [PubMed]
96. Turner-Warwick, M. Precapillary Systemic-Pulmonary Anastomoses. Thorax 1963, 18, 225–237 [CrossRef] [PubMed]
97. Myers, J.L.; Katzenstein, A.L. Epithelial necrosis and alveolar collapse in the pathogenesis of usual interstitial pneumonia. Chest 1988, 94, 1309–1311 [CrossRef] [PubMed]
98. Koyama, S.; Sato, E.; Tsukadaira, A.; Haniuda, M.; Numanami, H.; Kurai, M.; Nagai, S.; Izumi, T. Vascular endothelial growth factor mRNA and protein expression in airway epithelial cell lines in vitro. Eur. Respir. J. 2002, 20, 1449–1456 [CrossRef] [PubMed]
99. Ando, M.; Miyazaki, E.; Ito, T.; Hiroshige, S.; Nureki, S.I.; Ueno, T.; Takenaka, R.; Fukami, T.; Kumamoto, T. Significance of Serum Vascular Endothelial Growth Factor Level in Patients with Idiopathic Pulmonary Fibrosis. Lung 2010, 188, 247–252 [CrossRef] [PubMed]
100. Meyer, K.C.; Cardoni, A.; Xiang, Z.Z. Vascular endothelial growth factor in bronchoalveolar lavage from normal subjects and patients with diffuse parenchymal lung disease. J. Lab. Clin. Med. 2000, 135, 332–338 [CrossRef] [PubMed]
101. Murray, L.A.; Habiel, D.M.; Hohmann, M.; Camelo, A.; Shang, H.; Zhou, Y.; Coelho, A.L.; Peng, X.; Gulati, M.; Crestani, B. et al. Antifibrotic role of vascular endothelial growth factor in pulmonary fibrosis. JCI Insight 2017, 2 [CrossRef] [PubMed]
102. Simler, N.R.; Brenchley, P.E.; Horrocks, A.W.; Greaves, S.M.; Hasleton, P.S.; Egan, J.J. Angiogenic cytokines in patients with idiopathic interstitial pneumonia. Thorax 2004, 59, 581–585 [CrossRef] [PubMed]
103. Fagan, K.A.; McMurtry, I.F.; Rodman, D.M. Role of endothelin-1 in lung disease. Respir. Res. 2001, 2, 90–101 [CrossRef] [PubMed]
104. Renzoni, E.A. Neovascularisation in Idiopathic Pulmonary Fibrosis: too much or too little? Am. J. Respir. Crit. Care Med. 2004, 169, 1179–1180 [CrossRef] [PubMed]
105. Tzouvelekis, A.; Anevlavis, S.; Bouros, D. Angiogenesis in interstitial lung diseases: A pathogenetic hallmark or a bystander? Respir. Res. 2006, 7, 82 [CrossRef] [PubMed]
106. Lee, S.; Chen, T.T.; Barber, C.L.; Jordan, M.C.; Murdock, J.; Desai, S.; Ferrara, N.; Nagy, A.; Roos, K.P.; Iruela-Arispe, M.L. Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007, 130, 691–703 [CrossRef] [PubMed]
107. Stockmann, C.; Kerdiles, Y.; Nomaksteinsky, M.; Weidemann, A.; Takeda, N.; Doedens, A.; Torres-Collado, A.X.; Iruela-Arispe, L.; Nizet, V.; Johnson, R.S. Loss of myeloid cell-derived vascular endothelial growth factor accelerates fibrosis. Proc. Natl. Acad. Sci. USA 2010, 107, 4329–4334 [CrossRef] [PubMed]
108. Hamada, N.; Kuwano, K.; Yamada, M.; Hagimoto, N.; Hiasa, K.; Egashira, K.; Nakashima, N.; Maeyama, T.; Yoshimi, M.; Nakanishi, Y. Anti-vascular endothelial growth factor gene therapy attenuates lung injury and fibrosis in mice. J. Immunol. 2005, 175, 1224–1231 [CrossRef] [PubMed]
109. Chaudhary, N.I.; Roth, G.J.; Hilberg, F.; Muller-Quernheim, J.; Prasse, A.; Zissel, G.; Schnapp, A.; Park, J.E. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur. Respir. J. 2007, 29, 976–985 [CrossRef] [PubMed]
110. Farkas, L.; Farkas, D.; Ask, K.; Moller, A.; Gauldie, J.; Margetts, P.; Inman, M.; Kolb, M. VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats. J. Clin. Investig. 2009, 119, 1298–1311 [CrossRef] [PubMed]
111. Selman, M.; Pardo, A.; King, T.E., Jr. Hypersensitivity pneumonitis: Insights in diagnosis and pathobiology. Am. J. Respir. Crit. Care Med. 2012, 186, 314–324 [CrossRef] [PubMed]
112. Spagnolo, P.; Rossi, G.; Cavazza, A.; Bonifazi, M.; Paladini, I.; Bonella, F.; Sverzellati, N.; Costabel, U. Hypersensitivity Pneumonitis: A Comprehensive Review. J. Investig. Allergol. Clin. Immunol. 2015, 25, 237–250 [PubMed]
113. Selman, M.; Pardo, A.; Barrera, L.; Estrada, A.; Watson, S.R.; Wilson, K.; Aziz, N.; Kaminski, N.; Zlotnik, A. Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am. J. Respir. Crit. Care Med. 2006, 173, 188–198 [CrossRef] [PubMed]
114. Gifford, A.H.; Matsuoka, M.; Ghoda, L.Y.; Homer, R.J.; Enelow, R.I. Chronic inflammation and lung fibrosis: Pleotropic syndromes but limited distinct phenotypes. Mucosal Immunol. 2012, 5, 480–484 [CrossRef] [PubMed]
115. Willems, S.; Verleden, S.E.; Vanaudenaerde, B.M.; Wynants, M.; Dooms, C.; Yserbyt, J.; Somers, J.; Verbeken, E.K.; Verleden, G.M.; Wuyts, W.A. Multiplex protein profiling of bronchoalveolar lavage in idiopathic pulmonary fibrosis and hypersensitivity pneumonitis. Ann. Thorac. Med. 2013, 8, 38–45 [PubMed]
116. Jinta, T.; Miyazaki, Y.; Kishi, M.; Akashi, T.; Takemura, T.; Inase, N.; Yoshizawa, Y. The pathogenesis of chronic hypersensitivity pneumonitis in common with idiopathic pulmonary fibrosis: Expression of apoptotic markers. Am. J. Clin. Pathol. 2010, 134, 613–620 [CrossRef] [PubMed]
117. Navarro, C.; Ruiz, V.; Gaxiola, M.; Carrillo, G.; Selman, M. Angiogenesis in hypersensitivity pneumonitis. Arch. Physiol. Biochem. 2003, 111, 365–368 [CrossRef] [PubMed]
118. Yamashita, M.; Mouri, T.; Niisato, M.; Nitanai, H.; Kobayashi, H.; Ogasawara, M.; Endo, R.; Konishi, K.; Sugai, T.; Sawai, T. et al. Lymphangiogenic factors are associated with the severity of hypersensitivity pneumonitis. BMJ Open Respir. Res. 2015, 2, e000085 [CrossRef] [PubMed]
119. Alitalo, K. The lymphatic vasculature in disease. Nat. Med. 2011, 17, 1371–1380 [CrossRef] [PubMed]
120. Gutsche, M.; Rosen, G.D.; Swigris, J.J. Connective Tissue Disease-associated Interstitial Lung Disease: A review. Curr. Respir. Care Rep. 2012, 1, 224–232 [CrossRef] [PubMed]
121. Herrick, A.L. Pathogenesis of Raynaud’s phenomenon. Rheumatology 2005, 44, 587–596 [CrossRef] [PubMed]
122. Van Hal, T.W.; van Bon, L.; Radstake, T.R. A system out of breath: How hypoxia possibly contributes to the pathogenesis of systemic sclerosis. Int. J. Rheumatol. 2011, 824972 [CrossRef] [PubMed]
123. Steen, V.D.; Medsger, T.A. Changes in causes of death in systemic sclerosis, 1972–2002. Ann. Rheum. Dis. 2007, 66, 940–944 [CrossRef] [PubMed]
124. Freemont, A.J.; Hoyland, J.; Fielding, P.; Hodson, N.; Jayson, M.I. Studies of the microvascular endothelium in uninvolved skin of patients with systemic sclerosis: Direct evidence for a generalized microangiopathy. Br. J. Dermatol. 1992, 126, 561–568 [CrossRef] [PubMed]
125. Prescott, R.J.; Freemont, A.J.; Jones, C.J.; Hoyland, J.; Fielding, P. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J. Pathol. 1992, 166, 255–263 [CrossRef] [PubMed]
126. Roumm, A.D.; Whiteside, T.L.; Medsger, T.A., Jr.; Rodnan, G.P. Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum. 1984, 27, 645–653 [CrossRef] [PubMed]
127. Koenig, M.; Joyal, F.; Fritzler, M.J.; Roussin, A.; Abrahamowicz, M.; Boire, G.; Goulet, J.R.; Rich, E.; Grodzicky, T.; Raymond, Y. et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud’s phenomenon to systemic sclerosis: A twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum. 2008, 58, 3902–3912 [CrossRef] [PubMed]
128. Sulli, A.; Ruaro, B.; Alessandri, E.; Pizzorni, C.; Cimmino, M.A.; Zampogna, G.; Gallo, M.; Cutolo, M. Correlations between nailfold microangiopathy severity, finger dermal thickness and fingertip blood perfusion in systemic sclerosis patients. Ann. Rheum. Dis. 2014, 73, 247–251 [CrossRef] [PubMed]
129. Distler, O.; Distler, J.H.; Scheid, A.; Acker, T.; Hirth, A.; Rethage, J.; Michel, B.A.; Gay, R.E.; Müller-Ladner, U.; Matucci-Cerinic, M. et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ. Res. 2004, 95, 109–116 [CrossRef] [PubMed]
130. Marti, H.H.; Risau, W. Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors. Proc. Natl. Acad. Sci. USA 1998, 95, 15809–15814 [CrossRef] [PubMed]
131. Distler, O.; Del Rosso, A.; Giacomelli, R.; Cipriani, P.; Conforti, M.L.; Guiducci, S.; Gay, R.E.; Michel, B.A.; Brühlmann, P.; Müller-Ladner, U. et al. Angiogenic and angiostatic factors in systemic sclerosis: Increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res. 2002, 4, R11 [CrossRef] [PubMed]
132. Avouac, J.; Wipff, J.; Goldman, O.; Ruiz, B.; Couraud, P.O.; Chiocchia, G.; Kahan, A.; Boileau, C.; Uzan, G.; Allanore, Y. Angiogenesis in Systemic Sclerosis Impaired Expression of Vascular Endothelial Growth Factor Receptor 1 in Endothelial Progenitor-Derived Cells Under Hypoxic Conditions. Arthritis Rheum. 2008, 58, 3550–3561 [CrossRef] [PubMed]
133. Manetti, M.; Guiducci, S.; Romano, E.; Bellando-Randone, S.; Lepri, G.; Bruni, C.; Conforti, M.L.; Ibba-Manneschi, L.; Matucci-Cerinic, M. Increased plasma levels of the VEGF165b splice variant are associated with the severity of nailfold capillary loss in systemic sclerosis. Ann. Rheum. Dis. 2013, 72, 1425–1427 [CrossRef] [PubMed]
134. De Santis, M.; Bosello, S.L.; Capoluongo, E.; Inzitari, R.; Peluso, G.; Lulli, P.; Zizzo, G.; Bocci, M.; Tolusso, B.; Zuppi, C. et al. A vascular endothelial growth factor deficiency characterises scleroderma lung disease. Ann. Rheum. Dis. 2012, 71, 1461–1465 [CrossRef] [PubMed]
135. De Santis, M.; Ceribelli, A.; Cavaciocchi, F.; Crotti, C.; Massarotti, M.; Belloli, L.; Marasini, B.; Isailovic, N.; Generali, E.; Selmi, C. Nailfold videocapillaroscopy and serum VEGF levels in scleroderma are associated with internal organ involvement. Auto-Immun. Highlights 2016, 7, 5 [CrossRef] [PubMed]
136. Huang, J.; Maier, C.; Zhang, Y.; Soare, A.; Dees, C.; Beyer, C.; Harre, U.; Chen, C.W.; Distler, O.; Schett, G. et al. Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis. Ann. Rheum. Dis. 2017, 76, 1941–1948 [CrossRef] [PubMed]
137. Grundtman, C.; Tham, E.; Ulfgren, A.K.; Lundberg, I.E. Vascular endothelial growth factor is highly expressed in muscle tissue of patients with polymyositis and patients with dermatomyositis. Arthritis Rheum. 2008, 58, 3224–3238 [CrossRef] [PubMed]
138. Volpi, N.; Pecorelli, A.; Lorenzoni, P.; Di Lazzaro, F.; Belmonte, G.; Agliano, M.; Cantarini, L.; Giannini, F.; Grasso, G.; Valacchi, G. Antiangiogenic VEGF isoform in inflammatory myopathies. Mediat. Inflamm. 2013, 2013, 219313 [CrossRef] [PubMed]
139. Kikuchi, K.; Kubo, M.; Kadono, T.; Yazawa, N.; Ihn, H.; Tamaki, K. Serum concentrations of vascular endothelial growth factor in collagen diseases. Br. J. Dermatol. 1998, 139, 1049–1051 [CrossRef] [PubMed]
140. Tanaseanu, C.; Tudor, S.; Tamsulea, I.; Marta, D.; Manea, G.; Moldoveanu, E. Vascular endothelial growth factor, lipoporotein-associated phospholipase A2, sP-selectin and antiphospholipid antibodies, biological markers with prognostic value in pulmonary hypertension associated with chronic obstructive pulmonary disease and systemic lupus erithematosus. Eur. J. Med. Res. 2007, 12, 145–151 [PubMed]
141. Distler, J.H.; Strapatsas, T.; Huscher, D.; Dees, C.; Akhmetshina, A.; Kiener, H.P.; Tarner, I.H.; Maurer, B.; Walder, M.; Michel, B. et al. Dysbalance of angiogenic and angiostatic mediators in patients with mixed connective tissue disease. Ann. Rheum. Dis. 2011, 70, 1197–1202 [CrossRef] [PubMed]
142. Iwakawa, J.; Matsuyama, W.; Kubota, S.; Mitsuyama, H.; Suetsugu, T.; Watanabe, M.; Higashimoto, I.; Osame, M.; Arimura, K. Increased serum vascular endothelial growth factor levels in microscopic poly angiitis with pulmonary involvement. Respir. Med. 2006, 100, 1724–1733 [CrossRef] [PubMed]
143. Hashimoto, N.; Iwasaki, T.; Kitano, M.; Ogata, A.; Hamano, T. Levels of vascular endothelial growth factor and hepatocyte growth factor in sera of patients with rheumatic diseases. Mod. Rheumatol. 2003, 13, 129–134 [CrossRef] [PubMed]
144. Kuryliszyn-Moskal, A.; Klimiuk, P.A.; Sierakowski, S.; Ciolkiewicz, M. A study on vascular endothelial growth factor and endothelin-1 in patients with extra-articular involvement of rheumatoid arthritis. Clin. Rheumatol. 2006, 25, 314–319 [CrossRef] [PubMed]
145. Roth, D.A.; McKirnan, M.D.; Canestrelli, I.; Gao, M.H.; Dalton, N.; Lai, N.C.; Roth, D.M.; Hammond, H.K. Intracoronary delivery of an adenovirus encoding fibroblast growth factor-4 in myocardial ischemia: Effect of serum antibodies and previous exposure to adenovirus. Hum. Gene Ther. 2006, 17, 230–238 [CrossRef] [PubMed]
146. Sarkar, N.; Rück, A.; Källner, G.; Y-Hassan, S.; Blomberg, P.; Islam, K.B.; van der Linden, J.; Lindblom, D.; Nygren, A.T.; Lind, B. et al. Effects of intramyocardial injection of phVEGF-A165 as sole therapy in patients with refractory coronary artery disease—12-Month follow-up: Angiogenic gene therapy. J. Intern. Med. 2001, 250, 373–381 [CrossRef] [PubMed]